GET DAILY SIGNALSEncompass Health (EHC) Delivers Strong Q3 2026 Results with +8.9% Revenue Growth and Raised Guidance
Key Takeaways
- Encompass Health reported third-quarter 2026 net operating revenue of $1.61 billion, up 8.9% year over year (YoY).
- Adjusted earnings per share (EPS) came in at $1.52, comfortably above the Wall Street consensus estimate of $1.36.
- Management raised its full-year 2026 guidance for both net operating revenue and adjusted EPS.
- Strong demand for inpatient rehabilitation, supported by capacity expansion and easing labor costs, underpinned the results.
- For more context on this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Explore Trending AI Robots to see AI-driven trading strategies currently active in the market.
Earnings Context and Why It Matters
Encompass Health is the largest owner and operator of inpatient rehabilitation facilities (IRFs) in the United States, providing hospital-level rehabilitative care to patients recovering from stroke, neurological conditions, and other serious injuries. Its results are closely watched as a barometer of healthcare demand tied to an aging U.S. population. The third quarter follows consecutive beats earlier in 2026, when rising patient acuity and improved staffing retention drove revenue and margin gains. Investors are watching whether that momentum can persist, particularly as the company navigates evolving Medicare Advantage dynamics and expands capacity through new and small-format hospitals. I checked comparable names in the space using Tickeron’s AI Screener to see how EHC stacks up on key metrics.
Reported Results
For the third quarter ended September 30, 2026, Encompass Health reported net operating revenue of $1.61 billion, an 8.9% increase from $1.48 billion in the prior-year period and slightly above the consensus estimate of approximately $1.60 billion. Adjusted EPS reached $1.52, exceeding the $1.36 analysts had expected.
For the first nine months of 2026, net operating revenue totaled $4.79 billion, up from $4.39 billion a year earlier. Management raised its full-year 2026 outlook, now projecting net operating revenue of $6.45 billion to $6.50 billion (up from $6.41 billion to $6.49 billion) and adjusted EPS of $6.23 to $6.37 (up from $6.02 to $6.25). The quarter reflected continued strength in patient demand and improved operating leverage, with the company describing itself as "very pleased" with its performance.
Market Reaction and Investor Sentiment
Encompass Health's results arrived ahead of expectations on both the top and bottom lines, with the raised full-year guidance adding to a generally constructive setup heading into the print. The beat was driven by resilient demand for inpatient rehabilitation and continued improvement in labor efficiency, factors analysts have repeatedly cited as key to the company's margin trajectory. Wall Street sentiment on the stock remains broadly favorable, with the analyst community carrying a consensus Strong Buy rating and an average price target well above the shares' recent trading range. Investors will be parsing the earnings call for details on patient acuity trends and the pace of capacity additions, both of which are central to the stock's near-term narrative.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should focus on several themes. First, capacity expansion remains a core growth lever: the company is adding beds to existing hospitals and rolling out a small-format hospital strategy, including a hub-and-spoke model designed to reach markets where larger facilities may not be economical. The pace and returns on these additions will shape multi-year revenue growth.
Second, patient acuity, or the clinical complexity of admitted patients, is a key margin driver. Elevated acuity has supported revenue per discharge; any normalization could moderate growth. Third, Medicare Advantage (MA) reimbursement remains an area to watch, particularly the effectiveness of the company's admit-and-appeal strategy in converting initially denied admissions into paid care.
Finally, regulatory and cost dynamics matter. The Centers for Medicare & Medicaid Services (CMS) continue to expand value-based care programs, while labor costs have trended favorably as nurse turnover improves and premium labor spend declines. Sustained margin expansion will depend on balancing these factors with ongoing investment in growth. From what I see, these elements will determine whether the recent momentum holds into 2027.
Integrating Tickeron’s AI Tools into My Research
I often turn to Tickeron’s AI Screener when evaluating healthcare names like this one. It lets me quickly filter for stocks showing similar technical patterns or fundamental strength, helping me build context around earnings beats and sector trends without spending hours on manual screens. The tool has become a regular part of how I cross-check ideas before diving deeper into the numbers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EHC in downward trend: price dove below 50-day moving average on October 27, 2026
EHC moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend. In 27 of 35 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 77%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for EHC moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 49 similar instances where the indicator moved out of overbought territory. In 21 of the 49 cases, the stock moved lower in the following days. This puts the odds of a move lower at 43%.
The Momentum Indicator moved below the 0 level on October 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EHC as a result. In 43 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 48%.
The Moving Average Convergence Divergence Histogram (MACD) for EHC turned negative on October 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 26 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 54%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 32 of 49 cases where EHC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
Following a +1.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where EHC advanced for three days, in 192 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
EHC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 192 of 337 cases where EHC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 21 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron SMR rating for this company is 38 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. EHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.615) is normal, around the industry mean (204.200). P/E Ratio (19.539) is within average values for comparable stocks, (19.451). Projected Growth (PEG Ratio) (0.610) is also within normal values, averaging (2.498). Dividend Yield (0.007) settles around the average of (0.096) among similar stocks. P/S Ratio (2.021) is also within normal values, averaging (2.688).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of inpatient rehabilitation hospitals
Industry HospitalNursingManagement
Advertisement